83 related articles for article (PubMed ID: 17311836)
21. Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?
Hansen K; Lançon C; Toumi M
Eur J Health Econ; 2006 Mar; 7(1):19-29. PubMed ID: 16528579
[TBL] [Abstract][Full Text] [Related]
22. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective.
Altamura AC; Armadoros D; Jaeger M; Kernish R; Locklear J; Volz HP
Curr Med Res Opin; 2008 Aug; 24(8):2271-82. PubMed ID: 18588748
[TBL] [Abstract][Full Text] [Related]
23. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
24. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
25. Risperidone- and quetiapine-induced cholestasis.
Wright TM; Vandenberg AM
Ann Pharmacother; 2007 Sep; 41(9):1518-23. PubMed ID: 17666578
[TBL] [Abstract][Full Text] [Related]
26. Switching in the era of atypical antipsychotics. An updated review.
Weiden PJ
Postgrad Med; 2006 Sep; Spec No():27-44. PubMed ID: 17128659
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.
Lachaine J; Beauchemin C; Mathurin K; Gilbert D; Beillat M
J Med Econ; 2014 Apr; 17(4):296-304. PubMed ID: 24564402
[TBL] [Abstract][Full Text] [Related]
28. Atypical antipsychotics: considerations for Medicaid coverage.
Surles RC
Am J Manag Care; 2005 Sep; 11(8 Suppl):S248-53. PubMed ID: 16180963
[TBL] [Abstract][Full Text] [Related]
29. Atypical antipsychotics in the treatment of schizophrenia. Cost is a crucial issue.
Duggins R; Rhinds D; Hall W
BMJ; 2001 Apr; 322(7291):926; author reply 927-8. PubMed ID: 11302921
[No Abstract] [Full Text] [Related]
30. Use of multiattribute utility theory for formulary management in a health system.
Chung S; Kim S; Kim J; Sohn K
Am J Health Syst Pharm; 2010 Jan; 67(2):128-35. PubMed ID: 20065267
[TBL] [Abstract][Full Text] [Related]
31. [Cost analysis of the strategies in the treatment of schizophrenics: the place of sustained release injectable atypical antipsychotics].
Gasquet I; Bouhassira M; Launois R
Encephale; 2005; 31(4 Pt 1):517-8. PubMed ID: 16389719
[No Abstract] [Full Text] [Related]
32. Atypical antipsychotics in the treatment of schizophrenia. "Informed relationship between doctor and patient" does not exist in many parts of the world.
Lee S
BMJ; 2001 Apr; 322(7291):925-6; author reply 927-8. PubMed ID: 11302915
[No Abstract] [Full Text] [Related]
33. Priority setting in health care using multi-attribute utility theory and programme budgeting and marginal analysis (PBMA).
Peacock SJ; Richardson JR; Carter R; Edwards D
Soc Sci Med; 2007 Feb; 64(4):897-910. PubMed ID: 17141930
[TBL] [Abstract][Full Text] [Related]
34. A systematic review of health economic models and utility estimation methods in schizophrenia.
Németh B; Fasseeh A; Molnár A; Bitter I; Horváth M; Kóczián K; Götze Á; Nagy B
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):267-275. PubMed ID: 29347854
[TBL] [Abstract][Full Text] [Related]
35. Ziprasidone: pharmacology, clinical progress and therapeutic promise.
Buckley PF
Drugs Today (Barc); 2000 Aug; 36(8):583-9. PubMed ID: 12847582
[TBL] [Abstract][Full Text] [Related]
36. Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia.
Stroup TS; Jarskog LF
Evid Based Ment Health; 2010 May; 13(2):53. PubMed ID: 21856616
[No Abstract] [Full Text] [Related]
37. [Treatment of schizophrenia with emphasis on adherence--for the prevention of recurrences].
Ozaki N
Seishin Shinkeigaku Zasshi; 2006; 108(9):991-6. PubMed ID: 17137207
[No Abstract] [Full Text] [Related]
38. Employing multiple-attribute utility technology to evaluate publicity activities for cancer information and counseling programs in Japan.
Toh Y; Hagihara A; Shiotani M; Onozuka D; Yamaki C; Shimizu N; Morita S; Takayama T
J Cancer Policy; 2021 Mar; 27():100261. PubMed ID: 35559934
[TBL] [Abstract][Full Text] [Related]
39. Will the Proteus sensor enhance adherence to aripiprazole or other antipsychotics?
Masand P; Han C; Pae CU
Expert Rev Neurother; 2017 Apr; 17(4):319-321. PubMed ID: 28132567
[No Abstract] [Full Text] [Related]
40. Multi-attribute COVID-19 policy evaluation under deep uncertainty.
Mitcham J; Keisler J
Ann Oper Res; 2022 Mar; ():1-38. PubMed ID: 35283547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
